- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Sereti on novel agent NOV202 plus olaparib in prostate cancer
Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib (Lynparza) plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.
NOV202 is an investigational microtubule-targeting and vascular disrupting agent that demonstrated anticancer activity and tumor growth suppression of certain cancers, such as pancreatic and ovarian cancers, in preclinical research. Olaparib is FDA approved to treat men with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.
Sereti is a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre. She presented these results at the 2021 European Association of Urology Annual Congress.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
